Go Pro

Pediatrix Medical Group, Inc. (NYSE:MD) Stock Has Consensus Price Target of $26.60 According to Analysts

Pediatrix Medical Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst consensus is “Hold,” with five hold ratings and one buy rating among six analysts. The average 12-month price target is $26.60.
  • Pediatrix shares opened at $25.66, near the consensus target, with a 52-week range of $15.69 to $27.94. The stock has a $2.08 billion market capitalization and trades at a price-to-earnings ratio of 12.28.
  • The company exceeded quarterly expectations, reporting $0.63 in earnings per share versus the $0.59 consensus and $487.78 million in revenue, up 4.1% year over year. Institutional investors own 97.71% of outstanding shares.
  • Interested in Pediatrix Medical Group? Here are five stocks we like better.

Shares of Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) have been assigned an average recommendation of "Hold" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $26.60.

Several analysts recently commented on the stock. Weiss Ratings raised shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, September 9th. UBS Group increased their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a research note on Thursday, August 6th. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a "hold" rating in a research report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 13th.

Check Out Our Latest Report on Pediatrix Medical Group

Pediatrix Medical Group Stock Performance

Shares of MD opened at $25.66 on Friday. Pediatrix Medical Group has a 1 year low of $15.69 and a 1 year high of $27.94. The company's 50 day simple moving average is $26.39 and its 200 day simple moving average is $24.02. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of 12.28 and a beta of 0.64. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. During the same period last year, the business posted $0.53 EPS. The company's revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts predict that Pediatrix Medical Group will post 2.17 EPS for the current year.

Institutional Trading of Pediatrix Medical Group

Several hedge funds and other institutional investors have recently bought and sold shares of MD. Global Retirement Partners LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at approximately $33,000. Nykredit A S bought a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $35,000. Eurizon Capital SGR S.p.A. acquired a new position in Pediatrix Medical Group during the fourth quarter worth $33,000. Integrated Wealth Concepts LLC bought a new position in shares of Pediatrix Medical Group in the second quarter valued at approximately $53,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Pediatrix Medical Group in the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

(Get Free Report)

Pediatrix Medical Group, Inc is a physician-led healthcare services company that provides specialized medical care for women, infants and children. The company partners with hospitals and health systems to deliver care through physician practices, neonatal intensive care units and other hospital-based programs.

Its services include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric hospital medicine and other pediatric subspecialties. Pediatrix physicians care for patients before, during and after childbirth, as well as children requiring specialized or critical care.

Featured Stories

Analyst Recommendations for Pediatrix Medical Group (NYSE:MD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pediatrix Medical Group Right Now?

Before you consider Pediatrix Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.

While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines